Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors

Archives of Neurology

Volumn 57, Issue 10, 2000, Pages 1439-1443

  Wolozin, Benjamin ^a   Kellman, Wendy ^a   Ruosseau, Paul ^c   Celesia, Gastone G ^a   Siegel, George ^a,b  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b HINES VA HOSPITAL   (United States)

^c CARL T HAYDEN VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CHOLESTEROL; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL TARTRATE; MEVINOLIN; PRAVASTATIN; PROPRANOLOL; SIMVASTATIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR;

EID: 0033772113     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.57.10.1439     Document Type: Article

References (17)

1. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease
2. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: A case-control study
3. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
4. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology
5. Coronary artery disease, hypertension, ApoE, and cholesterol: A link to Alzheimer's disease?
6. Alpha2-macroglobulin complexes with and mediates the endocytosis of beta-amyloid peptide via cell surface low-density lipoprotein receptor-related protein
7. Alpha-2 macroglobulin is genetically associated with Alzheimer disease
8. Biochemistry of Alzheimer's and Prion diseases
9. Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons
10. Biochemical aspect of HMG CoA reductase inhibitors
11. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease
12. Clinical heterogeneity of probable Alzheimer's disease
13. Factors affecting the age of onset and rate of progression of Alzheimer's disease
14. Worldwide prevalence and incidence of dementia, Drugs Aging
15. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors
16. Development of neuropathology similar to Alzheimer's disease in transgenic mice overexpressing the 717(v-F) β-amyloid precursor protein
17. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model